FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	L	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							'	(,											
1. Name and Address of Reporting Person* <u>Dreyer Scott</u>						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC COLL								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title Other (specify					
(Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC.						3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024								X below) below) EVP & Chief Commercial Officer					
100 TECHNOLOGY CENTER DRIVE							4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) STOUGHTON MA 02072						X Form filed by One Reporting Person Form filed by More than One Reporting Person												- 1	
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - N	Non-Deri	vativ	e Sec	urit	ies A	cquir	ed, D	isposed o	f, or B	eneficial	y Owned					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execu Year) if any		Deemed ecution Date, ny onth/Day/Year)		action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a				es ally Following	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 05/23/20						24			M		51,209	A	\$24.03	190),127	D			
Common Stock 05/23/20					2024	24			S		51,209	D	\$33.824	138	8,918		D		
Common Stock 05/24/202					2024	24			M		23,791	A	\$24.03	162,709			D		
Common Stock 05/24/20				2024	24			S		56,807	D	\$33.9827	(2) 105	05,902		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, y or Exercise (Month/Day/Year) if any			Transaction of Decode (Instr. Se) Se(Ac) Dis		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Purchase)	\$24.03	05/23/2024			M			51,209		(3)	04/04/2028	Common Stock	51,209	\$0	23,791		D		
Stock Option (Right to Purchase)	\$24.03	05/24/2024						23,791		(3)	04/04/2028	Common Stock	23,791	\$0	0		D		

Explanation of Responses:

- 1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$33.36 to \$34.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- 2. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$33.68 to \$34.25, inclusive.
- 3. The option is fully vested and exercisable.

/s/ Shirley R. Kuhlmann as Attorney-In-Fact For Scott

05/28/2024

Dreyer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.